Pacira BioSciences (PCRX) Amortization of Deferred Charges (2023 - 2026)

Pacira BioSciences' Amortization of Deferred Charges history runs 4 years deep, the most recent figure standing at $577000.0 for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 31.72% year-over-year to $577000.0; the TTM figure through Mar 2026 stood at $2.7 million (down 19.4% YoY), while the FY2025 annual figure was $3.0 million, down 6.98% from the prior year.
• Amortization of Deferred Charges was $577000.0 for Q1 2026 at Pacira BioSciences, down from $677000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $1.4 million in Q4 2023 to a low of $577000.0 in Q1 2026.
• Historically, Amortization of Deferred Charges has averaged $811076.9 across 4 years, with a median of $763000.0 in 2024.
• The sharpest annual moves came in 2024 and 2025: Amortization of Deferred Charges sank 34.73% in 2024, then grew 24.08% in 2025.
• A 4-year view of Amortization of Deferred Charges shows it stood at $1.4 million in 2023, then tumbled by 34.73% to $938000.0 in 2024, then decreased by 27.83% to $677000.0 in 2025, then retreated by 14.77% to $577000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $577000.0 (Q1 2026), $677000.0 (Q4 2025), and $626000.0 (Q3 2025), per Business Quant data.